iPLEDGE The new isotretinoin registry iPledge timelines September: initial mailing to all prescribers October: Registration by pre-populated form Mid-October:

Slides:



Advertisements
Similar presentations
JPMorgan Chase Purchasing Card Training
Advertisements

Registration – Onsite Step 1: Click Sign-up Now!.
ASPIRE TRAINING RANDOMIZATION & INITIAL DISPENSING Cindy Jacobson, PharmD (MTN) Jen Berthiaume/Missy Cianciola (SCHARP)
COTOP Overview & Training. . HISTORY OF COTOP: The Chancellor’s Office is authorized to contract with community college districts to implement Section.
HIPAA Privacy Training. 2 HIPAA Background Health Insurance Portability and Accountability Act of 1996 Copyright 2010 MHM Resources LLC.
P E N N S Y L V A N I A C O A L I T I O N A G A I N S T D O M E S T I C V I O L E N C E P E N N S Y L V A N I A C O A L I T I O N A G A I N S T RAPE HIPAA.
Case Identification for the Missouri Perinatal Hepatitis B Prevention Program Libby Landrum, RN, MSN Viral Hepatitis Prevention Manager Bureau HIV, STD,
Health Insurance Portability Accountability Act of 1996 HIPAA for Researchers: IRB Related Issues HSC USC IRB.
Therapeutic Formula Training Part 2 Working with Medi-Cal May 2013.
Drug Utilization Review (DUR)
01 18 th March 2013 Investigator Meeting STAKT - Drug supply.
1.  Ask if the recipient is a smoker.  Encourage smoking cessation.  Discuss the effects of smoking on the infant to include: increased risk of prematurity,
P-1 Isotretinoin Pregnancy Risk Management Program.
Joint Dermatologic and Ophthalmic Drugs & Drug Safety and Risk Management Advisory Committee February 26 & 27, 2004 S ystem for T halidomide E ducation.
Medication History: Keeping our patients safe. How do we get all of the correct details?
WELLNESS REWARDS HealthyLiving-Lessons for Life January
EMR Work Flow KNIGHTS Clinic at Grace Medical Home.
1 Alvimopan RiskMAP Joyce Weaver, Pharm.D., BCPS Office of Surveillance and Epidemiology.
Medication Reconciliation Veterans Affairs North Texas Health Care System March 2008.
Safe Frame for 35mm Slides (delete from both Title and Slide masters before imaging slides or printing) Accutane FDA (PPP) 9/17/00 0 Targeted Pregnancy.
Need A RIDE? Presented by Melvin Thomas Manager Transportation IHCP Annual 2010 APP0045 (09/10)
Research and Development Protocol Submission and Continuing Review Processes Kimberly Summers, PharmD Assistant Chief for Clinical Research South Texas.
Student Technical Support
Administering Medications in Southeastern California Conference Schools.
Breast and Cervical Cancer Prevention and Treatment Program.
Implementing a Rapid HIV Testing Guideline for L&D NNEPQIN April 30, 2007.
Interim Report OTIS – North American Isotretinoin Information and Survey Line Toll-Free Number: Website: FDA Advisory.
Dermatologic and Ophthalmic Drugs Advisory Committee July 12, Evolution of Risk Management for Systemic Retinoids Evolution of Risk Management for.
Department of Health and Vanderbilt University Chronic Pain Guidelines Symposium Elizabeth Lund, Executive Director, Board of Nursing Linda Johnson, APN.
Epidemiology Center Isotretinoin Survey Allen A. Mitchell, MD Carla M. Van Bennekom, RN, MPH Slone Epidemiology Center At Boston University For presentation.
1 Module Six: Wrap-Up Screening Information System.
Varenicline PGD flow chart Process for PGD accredited Pharmacists.
INTRODUCTIONS A TIME FOR SHARING Hello and Welcome back !
Joint Dermatologic and Ophthalmic Drugs & Drug Safety and Risk Management Advisory Committee February 26 & 27, 2004 IsotretinoinIsotretinoin Background.
Sidney M. Wolfe M.D and Sherri Shubin M.D., M.P.H. Public Citizen’s Health Research Group FDA Drug Safety and Risk Management and Dermatologic and Ophthalmic.
DODAC and DSaRM Advisory Committee August 1, 2007 Pregnancy Registry and Root Cause Analysis Cynthia Kornegay, Ph.D. Division of Drug Risk Evaluation Office.
Maine’s Prescription Monitoring Program Daniel J. Eccher, MPH Project Coordinator Prescription Drug Misuse: A Community Challenge.
VA ADAP Update 7/13/2012. Enrollment Criteria Now Includes Effective 7/16/2012, all individuals on the waitlist with a CD4 count above 500 will enroll.
Quality Education for a Healthier Scotland Pharmacy Pharmaceutical Care Planning Vocational Training Scheme: Level = Stage 2 Arlene Shaw Specialist Clinical.
AFAMS Receive a Prescription Order (Dari) EO
**INSERT YOUR TITLE HERE**
Part B Portal Enhancements Training My care Ohio.
Accutane FDA (Section Name - Saver’s Initials) 3/9/00 12:50 PM 1 Risk Management Options Russell Ellison, MD Chief Medical Officer Vice President, Medical.
RESTICTED DRUGS Risk Evaluation and Mitigation Strategies--REMS
Dia-Foot Medicare Compliance Program MAKING IT EASY FOR YOUR PRACTICE TO RENDER THE DIABETIC SHOE PROGRAM.
ISOTRETINOIN RISK MANAGEMENT PROGRAM Background Information Genpharm Inc. Mylan/Bertek Pharmaceuticals Inc. Barr Laboratories, Inc. Ranbaxy Pharmaceuticals.
Monitoring Process for Pregnancy Category D or X Medications in Women of Childbearing Age Jody L. Lounsbery, PharmD, BCPS, Barbara Leone, MD University.
D-1 FCBPs Who Were Pregnant Prior to Therapy Start Date 1 Prescriber entered “false” pregnancy test results 1 Designee entered “false” pregnancy test results.
Medicines Authority 203,Level 3, Rue D’Argens, Gzira,GZR 1368 Tel: (+356) Fax: (+356) ov.mt Reporting.
Well on Target You’ll need your BCBS insurance card
Patient access – Ordering a prescription
Antibiotics: handle with care!
Registering for patient access
Management of Pregnancies
Using the Oregon POLST Registry
Charlotte Crist, BS, RN-BC, CCM, CPHQ
The Oregon POLST Registry
Protocol References Section Title 6.2 Entry Visit 5.1
Protocol References Section Title 6.2 Entry Visit 5.1
Moms program orientation
New Prescription Drugs Administrator – Express Scripts (ESI)
PMP Advisory Committee
April 12, 2017 Guy Reese, Program Integrity Manager
PRESCRIPTIONS Chap. 5.
2017 Modified Stage 2 Meaningful Use Objectives Overview Massachusetts Medicaid EHR Incentive Program September 19 & 20, 2017 September 19,
Using the Oregon POLST Registry
The Oregon POLST Registry
2019 medical benefit plans University of Nebraska.
Health Care Information Systems
Presentation transcript:

iPLEDGE The new isotretinoin registry

iPledge timelines September: initial mailing to all prescribers October: Registration by pre-populated form Mid-October: Receive patient kits November: –iPLEDGE goes live, doctors activate in system –New pts start on iPLEDGE November/December: transition old pts from SMART to iPLEDGE or finish course by 12/31 Jan 1, 2006: Not registered=no drug

iPLEDGE Background iPLEDGE is an mandatory FDA initiative All manufacturers of isotretinoin under one plan: –Ranbaxy - Sotret –Barr - Claravis –Genpharm (Bertek) - Amnesteem –Roche - Accutane Covance selected as vendor to design, build, implement and operate the enhanced iPLEDGE program

One Central Clearinghouse… One Program iPLEDGE Clearinghous e Physician Data Entry

Registration, Education and Activation Process All interested parties have responsibilities: Manufacturers Wholesalers Pharmacies Prescribers Patients

Distribution Manufacturers can only ship isotretinoin to registered wholesalers Wholesalers can only ship isotretinoin to registered pharmacies Registered pharmacies can only dispense isotretinoin when they receive iPLEDGE clearinghouse approval

How does a prescriber register and activate?

Prescriber Education Materials Registered Prescriber receives –Cover letter User name and password Prescriber educational materials Office staff designee(s) registration form and instructions Activation instructions sheet

Designee Clarification –Office staff designee--can enter information as an extension of an individual prescriber –Office delegate Doctors within a practice can designate each other to ensure continuum of care No need to change doctor’s name on registry There is no limit on designation(s) allowed Resident clinics - Designees and delegates have their own numbers

How do I enroll each patient into iPLEDGE?

Patient Registration by Prescriber –Logs onto system and enters: usual demographic data patient risk category (Male, WCBP, WNCBP) Confirmation of consent form(s) and HIPAA completion –Provide patient with iPLEDGE card –Provides and documents patient with counseling and educational materials

Patient Registration (all groups) Registers with the iPLEDGE system Attests that they have: –signed Informed consent form(s) –received education and counseling on isotretinoin & iPLEDGE requirements

Patient Registration (WCBP only) Additional informed consent Attest that they understand: –they should not become pregnant –they must use 2 forms of contraception for 30 days prior to, during and 30 days post- treatment –they must have monthly laboratory pregnancy testing –they must interact monthly with iPLEDGE system

Your patient needs to interact directly with iPLEDGE

iPLEDGE Program Walk-through Women of child bearing potential (WCBP) Women not of child bearing potential (WNCBP) and Males

WCBP Pre-Treatment Screening pregnancy test in prescriber’s office Prescriber documents in system –Patient registration –Informed consent form(s) completed –Patient education and counseling –Contraceptive methods discussed with patient –Date of negative screening pregnancy test (only time office test is okay) Initiate or continue appropriate contraception

WCBP monthly Laboratory-conducted pregnancy test –Results forwarded to prescriber –Lab must be CLIA certified Prescriber documents in system –Patient education & counseling –Contraceptive methods (must match patient input) –Pregnancy test results Prescriber provides prescription (paper, phone, fax, ) Patient interacts with iPLEDGE system –Answers monthly educational questions –Lists contraceptive methods (must match prescriber input)

WCBP – Completion of therapy Laboratory-conducted pregnancy test immediately upon treatment discontinuation Appropriate contraception continued for 30 days after last dose of isotretinoin Final laboratory-conducted pregnancy test 30 days post treatment discontinuation Pregnancy test results documented in system

Pre-Treatment (WNCBPs and Men) Prescriber enters into the system –Patient registration…men included –Informed consent form(s) completed –Patient education and counseling Prescriber provides prescription (paper, phone, fax, )

Each Treatment Month (WNCBPs and Males) Prescriber documents in system –Patient education & counseling Prescriber provides prescription (paper, phone, fax, ) WNCBP and men do not need to interact monthly with system

Every month for WCBP: Prescriber –Counsels pt, confirms contraception –Logs onto system to: Enter 2 forms of contraception patient has agreed to use Enter negative pregnancy test result Confirm pt counselled Patient –Has office visit and counselling –Has pregnancy test –Logs onto system and answers questions –Enters her 2 forms of BC

What is counselling? For everyone Risks of birth defects Don’t share drug Don’t donate blood Additional for WCBP Don’t get pregnant Use two forms of BC

Prescriber Notice All pregnancies should be reported directly to Covance through the iPLEDGE program – or call www.ipledgeprogram.com

What happens at the pharmacy?

Dispensing Isotretinoin (All Patients) Patient presents prescription to pharmacy within 7 days of the office visit –Can be paper, phone, fax, –No “yellow stickers” in iPLEDGE Pharmacist accesses iPLEDGE for prescription authorization If prescription authorized, isotretinoin dispensed at the pharmacy Pharmacy sticker prohibits sale after 7 days

Prescription NOT Authorized Reason for NO Authorization Instructions to Patient At Pharmacy Pregnancy test NOT entered Contact prescriber Prescriber has not confirmed 2 forms of birth control Contact prescriber Patient counseling NOT confirmed Contact prescriber Patient NOT interacting with iPLEDGE Patient to call iPLEDGE Pregnancy results are positive STOP taking medication and contact prescriber immediately.

Transition Plan (cont.) November 1 to December 31, 2005 Explanatory leaflet for prescribers and pharmacists to distribute to patients –Announces the launch of iPLEDGE –Encourages patients to talk to their physician –Provides information about iPLEDGE

If you have not received your iPLEDGE registration kit… log onto— or call

How will we cope with iPLEDGE? Kubler Ross stages of grieving Denial –I’m going to put this off as long as possible Anger –Threaten to stop prescribing Reality –Remember how important isotretinoin is Acceptance –Realize that the system is really easy once you get used to it